Advanced Search

Search Application

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search

Search term: pharmacology

Results 1 - 100 of 517 > >>
EC Number
Application
Commentary
homoserine dehydrogenase
pharmacology
enzyme is a target for inhibitor design for construction of antimicrobial agents
L-xylulose reductase
pharmacology
enzyme is a target for design and development of potent and specific structure-based inhibitors binding in the active site
mannitol-1-phosphate 5-dehydrogenase
pharmacology
inhibition of AfM1PDH might be a useful target for therapy of Aspergillus fumigatus infections
UDP-glucose 6-dehydrogenase
pharmacology
target for inhibitor design
3-hydroxyacyl-CoA dehydrogenase
pharmacology
the short-chain 3-hydroxyacyl-CoA dehydrogenase is a target for intervention in case of Alzheimer's disease and Parkinson's disease
11beta-hydroxysteroid dehydrogenase (NAD+)
pharmacology
the enzyme is an important therapeutic target for diabetes in humans
phosphogluconate dehydrogenase (NADP+-dependent, decarboxylating)
pharmacology
the enzyme is a target for inhibitor development for usage as drugs against African Trypanosomiasis
3-quinuclidinone reductase (NADPH)
pharmacology
stereospecific production of (R)-3-quinuclidinol, an important chiral building block for the synthesis of various pharmaceuticals
3-quinuclidinone reductase (NADH)
pharmacology
stereospecific production of (R)-3-quinuclidinol, an important chiral building block for the synthesis of various pharmaceuticals
3-quinuclidinone reductase (NADH)
pharmacology
stereospecific production of (R)-3-quinuclidinol, an important chiral building block for the synthesis of various pharmaceuticals. The 3-quinuclidinone reductase and Leifsonia sp. alcohol dehydrogenase genes are efficiently expressed in Escherichia coli cells. A number of constructed Echerichia coli biocatalysts (intact or immobilized) are applied to the resting cell reaction and optimized. Under the optimized conditions, (R)-(-)-3-quinuclidinolis synthesized from 3-quinuclidinone (15% w/v, 939 mM) giving a conversion yield of 100% for the immobilized enzyme. The optical purity of the (R)-(-)-3-quinuclidinol produced by the enzymatic reactions is above 99.9%
3-quinuclidinone reductase (NADH)
pharmacology
stereospecific production of (R)-3-quinuclidinol, an important chiral building block for the synthesis of various pharmaceuticals, high yield of (R)-3-quinuclidinol up to 916 g/L * d using a bioreduction approach
3-quinuclidinone reductase (NADH)
pharmacology
stereospecific production of (R)-3-quinuclidinol, an important chiral building block for the synthesis of various pharmaceuticals; stereospecific production of (R)-3-quinuclidinol, an important chiral building block for the synthesis of various pharmaceuticals. The 3-quinuclidinone reductase and Leifsonia sp. alcohol dehydrogenase genes are efficiently expressed in Escherichia coli cells. A number of constructed Echerichia coli biocatalysts (intact or immobilized) are applied to the resting cell reaction and optimized. Under the optimized conditions, (R)-(-)-3-quinuclidinolis synthesized from 3-quinuclidinone (15% w/v, 939 mM) giving a conversion yield of 100% for the immobilized enzyme. The optical purity of the (R)-(-)-3-quinuclidinol produced by the enzymatic reactions is above 99.9%
11beta-hydroxysteroid dehydrogenase
pharmacology
the enzyme is an important therapeutic target for diabetes in humans
11beta-hydroxysteroid dehydrogenase
pharmacology
isozyme 11beta-HSD1 is a target in treatment of metabolic diseases such as diabetes mellitus type 2 or obesity
prostaglandin-F synthase
pharmacology
enzyme is a target for cyclooxygenase-independent antineoplastic actions of nonsteroidal anti-inflammatory drugs
IMP dehydrogenase
pharmacology
the enzyme is a potential target as modulators in MTX chemotherapy of resistant cells, overview
quinate/shikimate dehydrogenase
pharmacology
enzymes of the shikimate pathway has been promoted as a target for the development of antimicrobial agents
zerumbone synthase
pharmacology
zerumbone is a predominating potential multi-anticancer agent
aspartate-semialdehyde dehydrogenase
pharmacology
enzyme is a target for development of antibiotics
aspartate-semialdehyde dehydrogenase
pharmacology
inhibitor design from enzyme three-dimensional structure
glyceraldehyde-3-phosphate dehydrogenase (phosphorylating)
pharmacology
lung-stage schistosomula immunofluorescence reactivity is diminished following antiserum absorption with reconbinant glyceraldehyde 3-phosphate dehydrogenase. Discussion of glyceraldehyde 3-phosphate dehydrogenase as a candidate vaccine antigen
aldehyde oxidase
pharmacology
metabolic inactivation of neonicotinoid insecticide substrates by enzyme system coupled with Drosophila nicotinic acetylcholine receptor
dihydroorotate dehydrogenase (NAD+)
pharmacology
drug design based upon selective enzyme inhibition
3-oxo-5alpha-steroid 4-dehydrogenase (NADP+)
pharmacology
enzyme is a target for drug developement
DELTA14-sterol reductase
pharmacology
enzyme is a potential antifungal target site, development of antifungal compounds
L-galactonolactone oxidase
pharmacology
because humans lack the capacity to synthesize ascorbate, the trypanosomal enzymes involved in ascorbate biosynthesis are interesting targets for drug therapy
dihydroorotate dehydrogenase (quinone)
pharmacology
A77 1726 inhibits cell growth in multiple myeloma cell lines at clinically achievable concentrations by induction of apoptosis. Inhibition of cell growth is partly due to inhibition of multiple myeloma cell proliferation. A77 1726 shows synergistic and additive activity together with genotoxic agents melphalan, treosulfan, and doxorubicin
glutaryl-CoA dehydrogenase (ETF)
pharmacology
targeted suppression of GCDH by lentivirus-mediated shRNA and excessive intake of lysine may be a useful cell model of glutaric aciduria type 1, overview
coproporphyrinogen dehydrogenase
pharmacology
the structure of HemN sets the stage for the development of inhibitors with antibacterial function due to the uniquely bacterial occurence of the enzyme
menaquinone-9 beta-reductase
pharmacology
menaquinone synthesis may be a drug target in Mycobacteria
menaquinone-9 beta-reductase
pharmacology
menaquinone synthesis may be a drug target in Mycobacterium tuberculosis
D-amino-acid oxidase
pharmacology
co-administration of the enzyme inhibitor 5-chloro-benzo[d]isoxazol-3-ol significantly enhances the efficacy of D-serine in attenuating prepulse inhibition deficits by administration of dizocilpine, an NMDA receptor antagonist. Therefore, co-administration of D-serine and a DAAO inhibitor has therapeutic potential for the treatment of schizophrenia
D-amino-acid oxidase
pharmacology
diminished DAO activity and elevations in D-serine may serve as an effective therapeutic intervention for the treatment of psychiatric symptoms
pteridine reductase
pharmacology
successful antifolate chemotherapy in Leishmania will have to target simultaneously both pterine reductase 1 and dihydrofolate reductase-thymidylate synthase
N1-acetylpolyamine oxidase
pharmacology
N,N'-butanedienyl butanediamine, i.e. MDL 72527 or CPC-200, a small molecule specific inhibitor of polyamine oxidase, effectively blocks androgen-induced reactive oxygen species production in human prostate cancer cells, as well as significantly delays prostate cancer progression and death in animals developing spontaneous prostate cancer
NAD(P)H dehydrogenase (quinone)
pharmacology
a series of lavendamycin analogues are tested in docking studies employing an X-ray derived NQO1 active site computational model, structure-based analogue design criteria are valid, resulting in the design of two analogues with high substrate specificity and selective toxicity toward NQO1-rich cells
factor-independent urate hydroxylase
pharmacology
urate oxidase is a potential therapeutic protein in the prevention and treatment of tumor lysis syndrome and hyperuricemia. However, its severe immunogenicity limits its clinical application. Engineering site-specific modifications of keto groups in urate oxidase by using evolved Methanocaldococcus jannaschii aminoacyl-tRNA synthetase(s)/suppressor tRNA pairs reduces its antigenicity. The mutated uricase exhibits decreased antigenic properties, while its catalytic activities remain unchanged
glutathione-disulfide reductase
pharmacology
enzyme is a target for enzyme inhibitor and antimalarial drug development
CoA-glutathione reductase
pharmacology
anti-staphylococcal agent, possible target for the design of selective inhibitors that would interrupt the thiol metabolism of the human pathogen Staphylococcus aureus
trypanothione-disulfide reductase
pharmacology
enzyme is a drug target
trypanothione-disulfide reductase
pharmacology
enzyme is a target for selective drug design
trypanothione-disulfide reductase
pharmacology
trypanothione reductase plays a central role in the trypanosomatid parasite’s defense against oxidative stress, trypanothione reductase is a promising target for antitrypanosomal drugs, 2-iminobenzimidazole class are potent trypanothione reductase inhibitors against Trypanosoma brucei rhodesiense and low cytotoxicity against human cells
trypanothione-disulfide reductase
pharmacology
trypanothione reductase plays a central role in the trypanosomatid parasite’s defense against oxidative stress, trypanothione reductase is a promising target for antitrypanosomal drugs, novel inhibitors are identified
trypanothione-disulfide reductase
pharmacology
trypanothione reductase plays a central role in the trypanosomatid parasite’s defense against oxidative stress, trypanothione reductase is a promising target for antitrypanosomal drugs, synthesis of dethiotrypanothione and related trypanothione analogues featuring ring-closing olefin metathesis macrocyclizations is described
trypanothione-disulfide reductase
pharmacology
trypanothione reductase plays a central role in the trypanosomatid parasite’s defense against oxidative stress, trypanothione reductase is a promising target for antitrypanosomal drugs, binding affinity towards trypanothione reductase and glutathione reductase of nitrofuran derivatives is assessed by standard molecular docking procedures and both, energy and structural output analysis, nitrofuran ligands display a slight preference to bind the closely related human glutathione reductase, they should not be considered as drugs with selective inhibition of trypanothione reductase
indoleamine 2,3-dioxygenase
pharmacology
first reaction in the tryptophan catabolic pathway in mammals
sulfur oxygenase/reductase
pharmacology
sulfur metabolism
Renilla-luciferin 2-monooxygenase
pharmacology
used as an assay for assessing potential liver toxicity by measuring GADD45-beta induction as an control for increased DNA damage
Renilla-luciferin 2-monooxygenase
pharmacology
investigations into regulation and functional roles of kinases
hyoscyamine (6S)-dioxygenase
pharmacology
tropane alkaloids including hyoscyamine, anisodamine, scopolamine and anisodine, are used medicinally as anticholinergic agents with increasing market demand, improvement of production by metabolic engineering introduction of genes encoding the branch-controlling enzyme tropinone reductase I and the downstream rate-limiting enzyme hyoscyamine-6beta-hydroxylase
6beta-hydroxyhyoscyamine epoxidase
pharmacology
tropane alkaloids including hyoscyamine, anisodamine, scopolamine and anisodine, are used medicinally as anticholinergic agents with increasing market demand, improvement of production by metabolic engineering introduction of genes encoding the branch-controlling enzyme tropinone reductase I and the downstream rate-limiting enzyme hyoscyamine-6beta-hydroxylase; tropane alkaloids including hyoscyamine, anisodamine, scopolamine and anisodine, are used medicinally as anticholinergic agents with increasing market demand, improvement of production by metabolic engineering introduction of genes encoding the branch-controlling enzyme tropinone reductase I and the downstream rate-limiting enzyme hyoscyamine-6beta-hydroxylase
proline 3-hydroxylase
pharmacology
the prolyl 3-hydroxylase P3H2 is a novel targets for epigenetic silencing in breast cancer; the prolyl 3-hydroxylase P3H3 is a novel targets for epigenetic silencing in breast cancer
anhydrotetracycline 6-monooxygenase
pharmacology
synthesis of chlortetracycline
nitric-oxide synthase (NADPH)
pharmacology
NO synthase can be used to gain insight into the biological role of endogenous agmatine
sterol 14alpha-demethylase
pharmacology
-
sterol 14alpha-demethylase
pharmacology
all known functional sterols lack a 14alpha-methyl group, and therefore the 14alpha-demethylation reaction has received much attention from the pharmaceutical and agriculture-chemical industry as a possible means to specifically control and inhibit sterol biosynthesis in mammals, fungi, and plant; target enzyme for azole antifungal agents. These specific inhibitors are of great importance as plant growth regulators, fungicides and herbicides in the agricultural and medical fields; target enzyme for the design of phyla-specific sterol 14alpha-demethylase inhibitors
sterol 14alpha-demethylase
pharmacology
target for cholesterol-lowering drugs
sterol 14alpha-demethylase
pharmacology
CYP51 is a key target for fungal antibiotic therapy
sterol 14alpha-demethylase
pharmacology
target enzyme for azole antifungal agents. These specific inhibitors are of great importance as plant growth regulators, fungicides and herbicides in the agricultural and medical fields
7-methylxanthine demethylase
pharmacology
methylxanthine intermediates of caffeine catabolism obtained by the action of N-demethylases have many applications. In medicine, theobromine and theophylline are used as diuretics, vasodilators, and myocardial stimulants. Monomethylxanthines can be converted to effective caffeine derivatives by chemical derivatization and hence can serve as interesting alternatives to caffeine. Xanthine also finds pharmaceutical application in drugs for treatment of asthma. The biotechnological potential of N-demethylases therefore lies not only in general decaffeination purposes but also in specific product recovery from caffeine
C-19 steroid 1alpha-hydroxylase
pharmacology
modification at the C-1 position of a steroid is of pharmaceutical interest. Biotransformation can overcome tedious multistep chemical synthesis
peptidylglycine monooxygenase
pharmacology
enzyme is an attractive target for development of anti-tumor compounds
tyrosinase
pharmacology
results indicate that the polyvinylpyrrolidone (PVP)-wrapped fullerene derivative (Radical Sponge) could be expected for its wide-ranged application as a whitening cosmetic material
tyrosinase
pharmacology
study of suicide inactivation and irreversible inhibition is important in the functional design of synthetic inactivators for therapeutic applications
tyrosinase
pharmacology
results of low cytotoxicity, high inhibition of melanin synthesis and lack of effect on gene expression suggest that p-hydroxybenzyl alcohol can be a potential agent for skin lightening to be used in cosmetic products
tyrosinase
pharmacology
(2R,3R)-taxifolin isolated from Benitade may possibly be a of new tyrosinase inhibitor alternative to cosmetic agents such as arbutin and kojic
tyrosinase
pharmacology
kurarinol, kuraridinol, and trifolirhizin are candidates as skin-whitening agents
tryptophan 5-halogenase
pharmacology
5-Br- and 5-Cl-tryptophan could presumably be applied as a pharmacologically attractive precursor of serotonin
squalene monooxygenase
pharmacology
squalene epoxidase is an attractive potential target for drugs used to inhibit the growth of pathogenic fungi or to lower cholesterol level in humans
xanthine oxidase
pharmacology
inhibition of xanthine oxidase is a potential therapeutic approach to diabetic neuropathy and vasculopathy
xanthine oxidase
pharmacology
the enzyme is a target in treatment of heart failure
ribonucleoside-diphosphate reductase
pharmacology
inhibition of RNRs is a proven strategy for combating cancer and some viruses
isopenicillin-N synthase
pharmacology
model system for study of endogenous functions of beta-lactams in bacteria
nicotinamide N-methyltransferase
pharmacology
molecular targets for cancer therapy and diagnosis
nicotinamide N-methyltransferase
pharmacology
NNMT as potential biomarker and therapeutic target
nicotinamide N-methyltransferase
pharmacology
biomarkers for cardiovascular risk factors
nicotinamide N-methyltransferase
pharmacology
the enzyme might be a good molecular target for lung cancer therapy
tRNA (guanine46-N7)-methyltransferase
pharmacology
enzymes NSUN2 and METTL1 are implicated in 5-fluorouracil sensitivity in HeLa cells. Interfering with methylation of tRNAs might provide a promising rationale to improve 5-fluorouracil chemotherapy of cancer
loganate O-methyltransferase
pharmacology
Catharanthus roseus is the sole commercial source for monoterpenoid indole alkaloids vindoline and catharanthine, components of the anticancer dimers vinblastine and vincristine
site-specific DNA-methyltransferase (adenine-specific)
pharmacology
enzyme is a target for antibiotics and antbiotic development
flavone/flavonol 7-O-methyltransferase
pharmacology
the enzyme reaction product rhmanetin, produced from quercetin, inhibits the formation of beta-amyloid. Rhamnetin holds great promise for use in therapeutic application in neurodegenerative disease, method evaluation, overview
protein-S-isoprenylcysteine O-methyltransferase
pharmacology
the enzyme is a target in anticancer therapy
macrocin O-methyltransferase
pharmacology
tylosin is used in veterinary medicine for treatment of infections caused by gram-positive bacteria and mycoplasma
macrocin O-methyltransferase
pharmacology
tylosin fermentation, antibiotic biosynthesis, enzyme catalyzes conversion of macrocin to tylosin in vivo
demethylmacrocin O-methyltransferase
pharmacology
tylosin fermentation, antibiotic biosynthesis
tRNA (cytosine34-C5)-methyltransferase
pharmacology
enzymes NSUN2 and METTL1 are implicated in 5-fluorouracil sensitivity in HeLa cells. Interfering with methylation of tRNAs might provide a promising rationale to improve 5-fluorouracil chemotherapy of cancer
protein N-terminal methyltransferase
pharmacology
NTMT1 inhibitors can be potential anticancer therapeutics
glycine hydroxymethyltransferase
pharmacology
L-serine is required for pharmaceutical purposes, availability of a sugar-based microbial process for its production is desirable, however, SHMT prevents overproduction of L-serine, control of the essential SHMT activity by a novel physiological approach
3-methyl-2-oxobutanoate hydroxymethyltransferase
pharmacology
enzyme could serve as target for anti-fungal drugs, since it is not present in mammals
3-methyl-2-oxobutanoate hydroxymethyltransferase
pharmacology
enzyme might be an attractive target for inhibitor design
transketolase
pharmacology
benfotiamine treatment activates glucose metabolism in INS-1 cells in high-glucose culture conditions and maximizes the cells' ability to synthesize insulin. Treatment activates glucokinase
acetolactate synthase
pharmacology
AHAS might be a target protein for the development of anti-tuberculosis therapeutics
arylamine N-acetyltransferase
pharmacology
NATs play an important role in the detoxication and, or bioactivation of numerous drugs and xenobiotics
arylamine N-acetyltransferase
pharmacology
arylamine N-acetyltransferases have a key role in the detoxication and metabolic activation of numerous xenobiotics, including therapeutic drugs and carcinogens
choline O-acetyltransferase
pharmacology
Nelumbo nucifera semen extract improves memory in rats with scopolamine-induced dementia through the induction of choline acetyltransferase expression and inhibition of acetylcholinesterase activity
carnitine O-palmitoyltransferase
pharmacology
CPT I, model enzyme for studies of fatty acid-induced apoptosis in cancer therapy
carnitine O-palmitoyltransferase
pharmacology
the data represent proof in principle that a pharmacological agent that stimulates hepatic fatty acid oxidation, perhaps acting on carnitine palmitoyltransferase 1a, could provide a novel approach to treatment of nonalcoholic fatty liver disease; the data represent proof in principle that a pharmacological agent that stimulates hepatic fatty acid oxidation, perhaps acting on carnitine palmitoyltransferase 1a, could provide a novel approach to treatment of nonalcoholic fatty liver disease
2-acylglycerol O-acyltransferase
pharmacology
[acyl CoA]monoacylglycerol acyltransferase 2 (MGAT2) is of interest as a target for therapeutic treatment of diabetes, obesity and other diseases which together constitute the metabolic syndrome
1-acylglycerophosphocholine O-acyltransferase
pharmacology
the enzyme is a potential therapeutic targets for the regulation of immune and inflammatory disorders
sterol O-acyltransferase
pharmacology
the results strongly support the idea that CS-505 could be promising as a therapeutic agent for the treatment of atherosclerosis
Results 1 - 100 of 517 > >>